BioCryst Pharmaceuticals | BCRX - Cash And Equivalent


BioCryst Pharmaceuticals reported $171.59M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Chugai Pharma JPY 426.6B 29.83B Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
DBV Technologies USD 229.2M 35.03M Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novavax USD 228.36M 12.27M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026